Jazz Pharmaceuticals (JAZZ) Gross Profit (2010 - 2026)

Jazz Pharmaceuticals' Gross Profit history runs 17 years deep, the most recent figure standing at $934.8 million for Q1 2026.

• In Q1 2026, Gross Profit rose 17.85% year-over-year to $934.8 million; the TTM figure through Mar 2026 stood at $3.9 billion (up 8.2% YoY), while the FY2025 annual figure was $3.8 billion, up 3.89% from the prior year.
• Gross Profit was $934.8 million for Q1 2026 at Jazz Pharmaceuticals, down from $1.0 billion in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $1.0 billion in Q4 2025 to a low of $698.4 million in Q1 2022.
• Historically, Gross Profit has averaged $872.9 million across 5 years, with a median of $870.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Gross Profit increased 27.83% in 2022, then slipped 1.65% in 2025.
• A 5-year view of Gross Profit shows it stood at $804.8 million in 2022, then gained by 12.42% to $904.7 million in 2023, then increased by 6.05% to $959.5 million in 2024, then climbed by 8.85% to $1.0 billion in 2025, then declined by 10.49% to $934.8 million in 2026.
• The last three Gross Profit figures came in at $934.8 million (Q1 2026), $1.0 billion (Q4 2025), and $997.2 million (Q3 2025), per Business Quant data.